Xcout Intel
NanoSyrinx competitors & alternatives
The 12 closest competitors and alternatives to NanoSyrinx among biotechnology companies — ranked by similarity to what NanoSyrinx actually does, not by market-cap band.
Subscribe to see NanoSyrinx’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About NanoSyrinx
NanoSyrinx Ltd. is a biotechnology company incorporated in England and Wales with headquarters in Warwick, focused on advancing targeted drug delivery platforms.
NanoSyrinx at a glance
NanoSyrinx is a biotechnology company headquartered in United Kingdom. It has raised at least $21M across the 2 funding rounds on record. Its most recent funding round, Series A, raised $13.3M in September 2024. Xcout tracks 11 named people at NanoSyrinx, including Tom Farrell (CEO).
NanoSyrinx leadership
- Tom FarrellCEO
- Dr. James LapworthChief Business Officer
- Dr. Marie McAvoyChief Scientific Officer
- Dr Edwin MosesChairman of the Board
- Dr. Joseph HealeyFounder
- Prof. Nicholas WaterfieldScientific Advisor and Co-founder
5 more named people on record for NanoSyrinx, with roles, board committees and tenure — see the full roster →
NanoSyrinx funding rounds
At least $21M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $13.3M | 7 named | |
| Seed | $8.6M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 NanoSyrinx competitors
Ranked by semantic similarity — how close each company is to NanoSyrinx by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotech
Thalia Therapeutics Plc, a specialized pharmaceutical company established in 1979 and headquartered in Chellaston, UK, focuses on developing advanced nanoparticle silica delivery systems. These innovative systems are designed to enhance the cellular uptake and effectiveness of various cancer treatments and vaccines. The company's product portfolio includes Nuvec, a unique silica nanoparticle delivery platform distinguished by its irregular surface structure that effectively encapsulates and safeguards genetic material such as siRNA, RNA, and DNA. Additionally, it offers Liptide, a specialized platform engineered for the targeted delivery of a proprietary siRNA sequence to silence fibrotic genes. Thalia Therapeutics is also advancing N4 101, an orally administered inflammation inhibitor currently undergoing pre-clinical evaluation for the treatment of inflammatory bowel disease, alongside ECP105, which is being developed to prevent ocular scarring. The firm, previously known as N4 Pharma Plc, officially rebranded to Thalia Therapeutics Plc in March 2026.
Biotech
NanoGhost is a biotechnology company that develops a targeted drug delivery platform using nanovesicles derived from the cell membranes of mesenchymal stem cells. The company serves the medical and pharmaceutical sectors by creating technologies designed to selectively target cancer and sites of inflammation for improved therapeutic delivery.
Similar biotechnology company
Phoreus Biotechnology, Inc. is a privately held biotechnology company founded in 2018 and headquartered in Olathe, Kansas. The company specializes in the development of proprietary nanocarriers for targeted drug delivery and enhanced treatments.
Similar biotechnology company
NERx Biosciences, Inc. is a small business enterprise headquartered in Indianapolis, Indiana, dedicated to the discovery and development of targeted therapeutics for cancer.
Similar biotechnology company
HelixNano is a biotechnology research company headquartered in Boston, Massachusetts, focused on developing advanced mRNA platform technologies for therapeutics.
Biotech
Mironid Limited is a privately held drug discovery company founded in 2015 and headquartered in Glasgow, Scotland. The patient-focused company develops innovative therapeutics to improve the treatment of various medical conditions.
Similar biotechnology company
BIND Therapeutics, Inc. is a clinical-stage nanomedicine company headquartered in Cambridge, Massachusetts. The company specializes in developing targeted and programmable therapeutics using its proprietary platform to treat various diseases.
Biotech
Nosis Biosciences develops receptor-targeted RNA medicines utilizing its proprietary AI-powered platform, Connexa, which combines physics-aware deep learning, single cell biology, and high-throughput chemistry. The company's platform designs gene-silencing therapeutics intended to treat chronic conditions across various cell types and organ systems, including the heart, lungs, kidneys, and brain.
Similar biotechnology company
pHLIP, Inc. is a privately held, clinical-stage biopharmaceutical company located in Kingston, Rhode Island, dedicated to improving patient outcomes using its proprietary pH-Low Insertion Peptide Platform.
Similar biotechnology company
Biora Therapeutics is a U.S. biotechnology company developing ingestible, device-based platforms for delivering biologic medicines to targeted areas of the gastrointestinal tract and into systemic circulation. Its technologies are intended for use by pharmaceutical and biotechnology companies developing oral or targeted biologic therapies.
Biotech
NeuroX1 Inc. is a for-profit biotechnology startup founded in 2021 with headquarters in Austin, Texas, operating a target identification and drug discovery platform that utilizes proprietary technology.
Biotech
Valerio Therapeutics is a biotechnology company that develops precision-guided therapeutics for complex and underserved diseases. It utilizes a proprietary V-Body conjugate platform, based on synthetic single-domain antibody libraries, to enable targeted drug delivery and deep tissue penetration.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of NanoSyrinx and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for NanoSyrinxand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →